2,2-dimethyl-hept-4t-en-3-one | 38343-01-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,2-dimethyl-hept-4t-en-3-one
• 英文别名: (E)-2,2-dimethylhept-4-en-3-one
• CAS: 38343-01-0
• 化学式: C₉H₁₆O
• 分子量: 140.225
• InChiKey: RRUARDXKFUXAAI-VOTSOKGWSA-N

物化性质

• 沸点：
  189.5±9.0 °C(Predicted)
• 密度：
  0.835±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,2-dimethyl-hept-4t-en-3-one 在 CuCN 作用下， 以 四氢呋喃 、 乙醚 、 苯 为溶剂， 反应 1.58h， 生成 (2SR,3SR,4RS,1'RS)-3-(1,1-dimethylethyl)-4-(1-methylpropyl)-2-phenyl-3-[(trimethylsilyl)oxy]oxetane
  参考文献：
  名称：

  1,3-Allylic Strain as a Control Element in the Paternò−Büchi Reaction of Chiral Silyl Enol Ethers:  Synthesis of Diastereomerically Pure Oxetanes Containing Four Contiguous Stereogenic Centers

  摘要：

  The facial diastereoselectivity in the Patemo-Buchi reaction of chiral silyl enol ethers and benzaldehyde was studied. The substituents (R(S), R(L)) at the stereogenic carbon atom (-C*HR(S)R(L)) attached to the beta-position of the silyl enol ether were varied in order to evaluate the influence of steric bulk and electronic effects. The combined yields for the two diastereomeric 3-(silyloxy)oxetanes a and b. range between 44% and 76%. In accordance with the 1,3-allylic strain model the facial diastereoselectivity (diastereomeric ratio (dr) = alb) was best with large(R(L) = t-Bu, SiMe(2)Ph) and polar (R(L) = OMe) substituents at the gamma-position of the silyl enol ether (dr up to >95/5). Two regioselective ring opening reactions were applied to the product oxetanes 29a, 50, and 51. They furnished diastereomerically pure diols (52, 53) and triols (31) in excellent yields.

  DOI：

  10.1021/ja963827v
• 作为产物：
  描述：

  (E)-2,2-Dimethyl-5-hepten-2-one 在 potassium tert-butylate 、 叔丁醇 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以33%的产率得到2,2-dimethyl-hept-4t-en-3-one
  参考文献：
  名称：

  二烯酮和三烯酮二价阴离子衍生物的产生：双重去质子化为充满光的π系统的途径

  摘要：

  共轭的不饱和羰基化合物及其类似物1是1,3,5 ...-试剂。这种内在的反应性的极性转换可通过生成二价阴离子来实现2，LUMO填充π的系统中，从氢化的前体，参见方案1和2的烯丙基化的酮的制备3a-d中，将酸衍生物的图3e-H ，9，10，12以及与二烯酮的11进行说明。他们的双脱质子化（→ 14，18，26，30，33，36，和40）依次用氢化钾和仲丁基锂/四甲基乙二胺（TMEDA）在THF中进行处理。证明了钾在第二个去质子化步骤中的决定性作用（表1和eqn（6））。这些Li / K双阴离子的鲜艳悬浮液或溶液用亲电子二苯甲酮淬灭。该产品（15，20，27，31，34，37，41）的结果只从ω反应性（d 5 -和d 7的两可双阴离子亲核体（反应性）CF式2中，n = 2,3）。

  DOI：

  10.1016/s0040-4020(01)93280-6

文献信息

• CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Araxes Pharma LLC

  公开号：US20180015087A1

  公开（公告）日：2018-01-18

  Conjugates of a cereblon-binding compound and compounds having modulatory activity against G12C mutant KRAS, HRAS or NRAS G12C proteins are provided. Methods associated with preparation and use of such conjugates, pharmaceutical compositions comprising such conjugates and methods to modulate the activity of G12C mutant KRAS, HRAS or NRAS G12C proteins for treatment of disorders, such as cancer, are also provided.

  提供了与谷氨酰脑结合化合物和具有调节活性对抗G12C突变KRAS、HRAS或NRAS G12C蛋白的化合物的共轭物。还提供了与制备和使用这种共轭物相关的方法，包括含有这种共轭物的药物组合物以及调节G12C突变KRAS、HRAS或NRAS G12C蛋白活性的方法，用于治疗癌症等疾病。
• PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER
  申请人：ODYSSEOS Andreani

  公开号：US20160376298A1

  公开（公告）日：2016-12-29

  The present invention relates to a theranostic system comprising a beacon and a compound selected from the group consisting of a quinazoline-based tyrosine kinase inhibitor and a natural product. The theranostic systems have use in the therapy and diagnosis of tyrosine kinase related malignancies.

  本发明涉及一种治疗系统，包括一个信标和从喹唑啉基酪氨酸激酶抑制剂和天然产物组成的化合物中选择的一种。这种治疗系统在酪氨酸激酶相关恶性肿瘤的治疗和诊断中有用。
• THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE
  申请人：Cao Sheldon

  公开号：US20140213580A1

  公开（公告）日：2014-07-31

  Provided are compounds with the following structure, formula (I) pharmaceutically acceptable salts thereof, use of those compounds for treating cancer and pharmaceutical compositions comprising those compounds.

  提供具有以下结构和式（I）的化合物，其药学上可接受的盐，使用这些化合物治疗癌症的方法以及包含这些化合物的制药组合物。
• INHIBITORS OF KRAS G12C
  申请人：Araxes Pharma LLC

  公开号：US20150239900A1

  公开（公告）日：2015-08-27

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R 1 , R 2a , R 3a , R 3b , R 4a , R 4b , G 1 , G 2 , L 1 , L 2 , m 1 , m 2 , A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了具有抑制G12C突变KRAS蛋白活性的化合物。这些化合物具有以下结构（I）：或其药学上可接受的盐、互变异构体、前药或立体异构体，其中R1、R2a、R3a、R3b、R4a、R4b、G1、G2、L1、L2、m1、m2、A、B、W、X、Y、Z和E的定义如本文所述。还提供了与制备和使用这些化合物相关的方法，包括含有这些化合物的制药组合物以及用于治疗癌症等疾病的调节G12C突变KRAS蛋白活性的方法。
• INHIBITORS OF KRAS G12C MUTANT PROTEINS
  申请人：Araxes Pharma LLC

  公开号：US20160108019A1

  公开（公告）日：2016-04-21

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein R 1 , R 2 , R 3a , R 3b , R 4a , R 4b , G 1 , G 2 , L, m 1 , m 2 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了作为G12C突变KRAS蛋白抑制剂活性的化合物。该化合物具有以下结构（I）：或其药学上可接受的盐、互变异构体、立体异构体或前药，其中R1、R2、R3a、R3b、R4a、R4b、G1、G2、L、m1、m2和E的定义如本文所述。还提供了与制备和使用这种化合物相关的方法，包括包含这种化合物的制药组合物以及用于治疗癌症等疾病的调节G12C突变KRAS蛋白活性的方法。